CL2017001273A1 - Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof. - Google Patents

Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.

Info

Publication number
CL2017001273A1
CL2017001273A1 CL2017001273A CL2017001273A CL2017001273A1 CL 2017001273 A1 CL2017001273 A1 CL 2017001273A1 CL 2017001273 A CL2017001273 A CL 2017001273A CL 2017001273 A CL2017001273 A CL 2017001273A CL 2017001273 A1 CL2017001273 A1 CL 2017001273A1
Authority
CL
Chile
Prior art keywords
hydrolyzate
pharmaceutical compositions
compositions containing
immunity
probiotic
Prior art date
Application number
CL2017001273A
Other languages
Spanish (es)
Inventor
Castro Inostroza; Maria Piderit Moreno Juan Pablo Mellado; Maria Jose Aguajo: Rodrigo Borquez Erica
Original Assignee
Univ San Sebastian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ San Sebastian filed Critical Univ San Sebastian
Priority to CL2017001273A priority Critical patent/CL2017001273A1/en
Publication of CL2017001273A1 publication Critical patent/CL2017001273A1/en
Priority to PCT/CL2018/050024 priority patent/WO2018209457A1/en
Priority to ARP180101289 priority patent/AR112354A1/en
Priority to ECSENADI201988005A priority patent/ECSP19088005A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención desarrollada en el campo de los productos biotecnológicos naturales, describe un compuesto basado en hidrolizado proteico soluble (HPS) de la cepa probiótica Lactobacillus spp DSM32447. En particular, la invención refiere a un compuesto de origen natural, inocuo que confiere inmunidad de mucosas, se describe el método de obtención, composiciones farmacéuticas que lo contienen y uso de las mismas.</p><p> The invention developed in the field of natural biotechnological products describes a compound based on soluble protein hydrolyzate (HPS) of the probiotic strain Lactobacillus spp DSM32447. In particular, the invention relates to a compound of natural origin, harmless that confers immunity from mucous membranes, the method of production, pharmaceutical compositions containing it and use thereof are described. </p>

CL2017001273A 2017-05-17 2017-05-17 Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof. CL2017001273A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CL2017001273A CL2017001273A1 (en) 2017-05-17 2017-05-17 Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.
PCT/CL2018/050024 WO2018209457A1 (en) 2017-05-17 2018-05-14 Oropharyngeal aerosol comprising a hydrolysate derived from a probiotic with effects on the immunity of the genitourinary tract, method for producing the hydrolysate, pharmaceutical compositions containing same and use thereof
ARP180101289 AR112354A1 (en) 2017-05-17 2018-05-16 OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM
ECSENADI201988005A ECSP19088005A (en) 2017-05-17 2019-12-11 OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017001273A CL2017001273A1 (en) 2017-05-17 2017-05-17 Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.

Publications (1)

Publication Number Publication Date
CL2017001273A1 true CL2017001273A1 (en) 2018-03-16

Family

ID=63046376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001273A CL2017001273A1 (en) 2017-05-17 2017-05-17 Oropharyngeal spray composed of a hydrolyzate derived from a probiotic that has an impact on the immunity of the genitourinary tract, method of obtaining the hydrolyzate, pharmaceutical compositions containing it and use thereof.

Country Status (4)

Country Link
AR (1) AR112354A1 (en)
CL (1) CL2017001273A1 (en)
EC (1) ECSP19088005A (en)
WO (1) WO2018209457A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674826A (en) * 2019-01-31 2019-04-26 吉林省知遇科技有限公司 A kind of probiotic composition for nursing female reproductive system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2087094T3 (en) * 2006-11-17 2014-08-29 Sca Hygiene Prod Ab Lactobacillus fermentum ess-1, dsm17851 and its use for the treatment and/or prevention of candidiasis and urinary tract infections
EP2540818A1 (en) * 2008-09-04 2013-01-02 OM Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
CL2009001511A1 (en) * 2009-07-02 2009-10-23 Univ De Concepcion 61 02% Pharmaceutical formulation comprising viable strains of lactobacillus acidophilus lpv 31 and l. plantarum lpm-01, which is useful in the prevention and / or treatment of urinary infections and in improving the immune response in immunocompromised patients.
GB201409541D0 (en) * 2014-05-29 2014-07-16 Univ Manchester Probiotic Bacteria
EP3064072A1 (en) * 2015-02-11 2016-09-07 AB-Biotics S.A. Probiotic lactobacillus strains for use in treating urinary tract infections

Also Published As

Publication number Publication date
AR112354A1 (en) 2019-10-23
ECSP19088005A (en) 2020-05-29
WO2018209457A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CO2019004886A2 (en) Peptides that can unfold and insecticidal and nematicidal proteins that comprise them
CR20160499A (en) STABLE COMPOSITIONS OF IODINE NOT IN COMPLEX AND METHODS OF USE
NI201600028A (en) POLYPEPTIDE FOR THE HYDROLYTIC EXCISION OF ZEARALENONE AND / OR DERIVATIVES OF ZEARALENONE, POLYNUCLEOTIDE ISOLATED FROM THE SAME AND POLYEPTIDE CONTAINING ADDITIVE, USE AND PROCEDURE OF THE SAME.
AR104725A1 (en) SURFACTANT COMPOSITIONS AND DETERGENTS CONTAINING ETOXYLED GLYCERINE
ES2722773T3 (en) Modified Meningococcal fHbp Polypeptides
AR106481A1 (en) LIQUID DETERGENT COMPOSITION
AR101742A1 (en) CALCITONINE AND AMILINE RECEIVER AGONIST
AR120721A2 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE
MX2016014564A (en) Vaccine against acinetobacter baumannii based on cellular components deficient in lipopolysaccharide.
NI201700156A (en) LIPID PEPTIDES RESISTANT TO PROTEASES
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2019010367A (en) Aqueous anti-pd-l1 antibody formulation.
MX2018008019A (en) Peptide tag and tagged protein including same.
MX2017016588A (en) Novel triterpene-glycosides as sweeteners or sweetener enhancer.
MX2019004580A (en) Pharmaceutical formulations and methods of making the same.
AR106482A1 (en) LIQUID DETERGENT COMPOSITION
CL2017000130A1 (en) Acetic acid recovery from wood acetylation
ECSP19088005A (en) OROPHARYNGEAL AEROSOL COMPOSED BY A HYDROLYZED DERIVED FROM A PROBIOTIC THAT HAS AN IMPACT ON THE IMMUNITY OF THE GENITOURINARY TRACT, METHOD OF OBTAINING THE HYDROLYZED, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, AND USE OF THEM
MX2018014966A (en) Protease-resistant mono-lipidated peptides.
CL2018001680A1 (en) Compositions and methods of use of new strains of lactobacillus fermentum
IN2013DE01652A (en)
MX362058B (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
WO2015149085A3 (en) Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
TH142498S (en) Saliva tube